Skinhealth Systems Inc

Skinhealth Systems Inc(SKIN)股票分析

$10.350

-0.655 (-6.33%)收盘时

Loading chart…
最高
11.675
开盘
11.580
成交量加权均价
10.75
成交量
23.07K
市值
234.90M
最低
10.228
成交额
248.01K
企业价值/息税折旧摊销前利润(TTM)
5.98

SkinHealth Systems Inc., formerly The Beauty Health Company, is a global medical aesthetics company. The Company, anchored by Hydrafacial, a professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp with Keravive, combines advanced device technology, proprietary consumables, and clinical validation to deliver treatment experiences through an omnichannel network of providers worldwide. Hydrafacial specializes in the category of hydradermabrasion with its patented delivery system that cleanses, extracts and hydrates the skin with proprietary solutions and serums. The treatment extends to the scalp through its HydraScalp powered by Keravive treatment, which is designed to support the hair's natural growth. SkinStylus specializes in nano-channeling and microneedling where its products are designed to provide either a non-invasive (nano-channeling) or minimally-invasive (microneedling) skin treatment to individuals.

AI 分析 of Skinhealth Systems Inc (SKIN)

持有

Currently, SKIN is not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $10.38, which is significantly below its 52-week high of $34.80, indicating a potential for recovery but also substantial risk. The RSI is at 44.91, suggesting it is near neutral territory, and the forward P/E ratio is extremely high at 106.38, indicating that the stock may be overvalued at this price. The main risk is the analyst downgrade from TD Cowen, which lowered its price target to $0.90, reflecting concerns about revenue and competition.

估值指标

Skinhealth Systems Inc(SKIN)当前预期市盈率为 106.38,5 年平均预期市盈率为 14.58。

预期市盈率

合理
5 年均值 P/E
14.58
当前P/E
106.38
高估
162.12
低估
-132.96

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
25.64
当前EV/EBITDA
5.98
高估
63.30
低估
-12.03

预期市销率

合理
5 年均值 P/S
2.30
当前P/S
0.24
高估
4.99
低估
-0.40

Alphio AI 对 SKIN 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%SKIN

$1.44

情景价格

基

基准

基准 · 50%SKIN

$1.26

情景价格

悲

悲观

悲观 · 25%SKIN

$1.05

情景价格

持有 SKIN 的大户

L

Linden Advisors LP

+ 持有SKIN

+60.32%

3个月收益率

事件时间线

2026-11-05 (ET)

18:00:00

Company Raises FY26 EBITDA Outlook to $48M-$50M

18:00:00

SkinHealth Systems Reports Q3 Revenue of $69.2M

2026-10-13 (ET)

20:00:00

Beauty Health Co Trading Halted, News Pending

2026-10-01 (ET)

06:30:00

SkinHealth Systems Launches SkinStylus Device in Europe

2026-08-26 (ET)

09:30:00

SkinHealth Systems Launches Hydrafacial Impact Education Program

资讯

SKIN 常见问题 —— 由 Alphio AI 解答

SkinHealth Systems Inc., formerly The Beauty Health Company, is a global medical aesthetics company. The Company, anchored by Hydrafacial, a professional skincare treatment, and supported by complementary offerings including SkinStylus microneedling and HydraScalp with Keravive, combines advanced device technology, proprietary consumables, and clinical validation to deliver treatment experiences through an omnichannel network of providers worldwide. Hydrafacial specializes in the category of hydradermabrasion with its patented delivery system that cleanses, extracts and hydrates the skin with proprietary solutions and serums. The treatment extends to the scalp through its HydraScalp powered by Keravive treatment, which is designed to support the hair's natural growth. SkinStylus specializes in nano-channeling and microneedling where its products are designed to provide either a non-invasive (nano-channeling) or minimally-invasive (microneedling) skin treatment to individuals. It operates in the Consumer Non-Cyclicals sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Currently, SKIN is not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $10.38, which is significantly below its 52-week high of $34.80, indicating a potential for recovery but also substantial risk. The RSI is at 44.91, suggesting it is near neutral territory, and the forward P/E ratio is extremely high at 106.38, indicating that the stock may be overvalued at this price. The main risk is the analyst downgrade from TD Cowen, which lowered its price target to $0.90, reflecting concerns about revenue and competition.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易